Loading company…
Riskpilot
← Back to search
Sign in
Get full access
HUBRO BIOSCIENCE AS
AS
Bankrupt
Org 933476561
Camilla Colletts vei 18, 0258 Oslo
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2024
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 500K
EBITDA margin
-220.4%
Equity ratio
-240.0%
Financial strength
Net profit 2024
NOK -1,1M
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
-1M
2024
Key figures
Annual report 2024
Revenue
NOK 500K
—
EBITDA
NOK -1,1M
—
Net profit
NOK -1,1M
—
Total assets
NOK 448K
—
Equity
NOK -1,1M
—
Employees
—
—
Company information
Legal name
HUBRO BIOSCIENCE AS
Org number
933476561
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. mai 2024
Share capital
NOK 30 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder i fellesskap.
Company purpose
Utvikling og salg av biomedisinske produkter og tjenester. Formålet kan fremmes ved deltakelse i eller samarbeid med andre foretak i inn- og utland.
Contact
Address
Camilla Colletts vei 18, 0258 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
1M
2024
EBITDA
NOK millions
0M
-0M
-1M
-1M
-1M
-1M
2024
Income statement
NOK thousands
Item
2024
Revenue
500
Staff expenses
−466
EBITDA
−1 102
Depreciation & amort.
−0
EBIT
−1 102
Net financials
−3
Profit before tax
−1 104
Tax
−0
Net profit
−1 104
Balance sheet
NOK thousands
Item
2024
Total assets
448
Equity
−1 074
Long-term debt
1 500
Short-term debt
22
Total debt
1 522
Financial ratios
5-year trend
EBITDA margin
-220.4%
This company
15.8%
Market median
-1495% vs market
2024
2024
Equity ratio
-240.0%
This company
38.2%
Market median
-728% vs market
2024
2024
Return on equity
-110448600.0%
This company
18.4%
Market median
-600264230% vs market
2024
2024
Net profit margin
-220.9%
This company
8.1%
Market median
-2827% vs market
2024
2024
Asset turnover
1.12×
This company
1.12×
Market median
+0% vs market
2024
2024
Debt / equity
1.42×
This company
0.62×
Market median
-129% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-04-30 – 2024-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
JA
Jon Amund Eriksen
Chief Executive Officer
Chief Executive Officer
2024
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
TA
Tom Arne Thorsen
Deputy Chairman
2024
—
—
RM
Robert Matthew Miller
Board of Directors
2024
—
—
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Algot Invest As
Company
60.0%
60.0%
2024
TIMMUNO AS
Company
40.0%
40.0%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
TIMMUNO AS
HUBRO BIOSCIENCE AS
(this company)
Board network connections
Board members of HUBRO BIOSCIENCE AS also hold positions in
0
other companies.
Person
Role here
Other companies
Jon Amund Eriksen
Chief Executive Officer
0 companies
Tom Arne Thorsen
Deputy Chairman
0 companies
Robert Matthew Miller
Board of Directors
0 companies